Spero Therapeutics, Inc.
NASDAQ: SPRO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Esther Rajavelu
- Employees
- 32
- Headquarters
- Cambridge, United States
- IPO year
- 2017
- Market cap
- $121.6M
- Website
- https://sperotherapeutics.com
Loading SPRO…
Loading profile data…Frequently asked questions about SPRO
What does Spero Therapeutics, Inc. (SPRO) do?
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipene...
Where does SPRO trade?
Spero Therapeutics, Inc. (SPRO) trades on the NASDAQ Global Select.
What sector is SPRO in?
Spero Therapeutics, Inc. (SPRO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Spero Therapeutics, Inc.?
Esther Rajavelu is the chief executive officer of Spero Therapeutics, Inc. (SPRO).
Where is Spero Therapeutics, Inc. headquartered?
Spero Therapeutics, Inc. is headquartered in United States.
Does SPRO pay a dividend?
Spero Therapeutics, Inc. (SPRO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SPRO go public?
Spero Therapeutics, Inc. (SPRO) completed its initial public offering in 2017.